Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

TAK - Takeda Pharmaceutical Company Limited... | Finranks

Home

/

TAK

T

Takeda Pharmaceutical Company Limited (TAK)

NYQ – Real vaqt narxi. Valyuta: USD

17.41

-0.07 (-0.40%)

Bozor ochiq: Aug 12, 2026, 12:39 PM EDT

17.88

+0.40 (2.29%)

Oldingi bozordan keyin: Aug 11, 2026, 7:55 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda Pharmaceuticals (TAK) remains a hold, with shares near 52-week highs and uncertainty about a major successor to Entyvio. TAK's Q1 showed 10% revenue growth, but bottom-line weakness from higher taxes and lower operating cash flow due to mounting receivables. Orzeyful's FDA approval is promising, but its commercial impact is likely limited compared to Entyvio; pipeline drugs like zasocitinib offer longer-term potential, but how much is as yet uncertain.

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) Orzeyful (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people's lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to tr.

US FDA approves Takeda's sleep disorder pill

US FDA approves Takeda's sleep disorder pill

The FDA has approved Takeda Pharmaceuticals' oral drug for narcolepsy, the U.S. health regulator said on Wednesday, backing ‌the first treatment that targets all the symptoms of the rare sleep disorder.

Videolar

No Data

There is no data to display

Press-relizlar

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people's lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to tr.